Quick Answer
Sonoma Pharmaceuticals, Inc. reported Revenue (ASC 606) of $18.63 million for fiscal year 2021.
Sonoma Pharmaceuticals, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2021 | $18.63M | +3.9% |
| 2020 | $17.93M | -5.5% |
| 2019 | $18.97M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| December 31, 2021 | $2.90M | -41.2% | -22.5% |
| September 30, 2021 | $3.74M | -35.1% | +1.6% |
| June 30, 2021 | $3.68M | -36.1% | -25.4% |
| December 31, 2020 | $4.94M | +12.3% | -14.4% |
| September 30, 2020 | $5.77M | +22.0% | +0.0% |
| June 30, 2020 | $5.77M | +31.5% | +31.2% |
| December 31, 2019 | $4.39M | — | -7.0% |
| September 30, 2019 | $4.73M | — | +7.8% |
- Sonoma Pharmaceuticals, Inc. showed an increase of +3.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2019–2021 period, Sonoma Pharmaceuticals, Inc.’s revenue (asc 606) has declined by 1.8% (from $18.97 million to $18.63 million).
- The most recent figure is from Sonoma Pharmaceuticals, Inc.’s fiscal year 2020 report (Form 10-K), filed with the SEC on July 14, 2021.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: